Question to the Department of Health and Social Care:

To ask Her Majesty's Government, further to the remarks by Lord Kamall on 31 January (HL Deb col 621), what progress they have made in meeting the target of 5 million secured patient courses of antiviral treatments for COVID-19.

The Government has secured 4.98 million patient courses of oral antiviral treatments. This includes 2.75 million patient courses of nirmatrelvir and ritonavir, co-packaged as Paxlovid, from Pfizer and 2.23 million patient courses of molnupiravir from Merck Sharp and Dohme. We continue to receive regular supplies of these antivirals which are available to eligible patients via the PANORAMIC trial and COVID Medicine Delivery Units in England and equivalent arrangements in the devolved administrations.